chlorido, phosphane or glucosethiolato ligands, n = 0 or 1) have been synthesized and fully characterized using different techniques, including NMR, IR and Far-IR, mass spectrometry, as well as elemental analysis. The crystal structure of one compound has been solved using X-ray diffraction methods. All compounds were tested in vitro in five human cancer cell lines including lung, breast, colon and ovarian cancer cells. For comparison purposes, all compounds were also tested in a model of human healthy cells from embryonic kidney. Notably, all new compounds were more toxic than their cyclometallated precursor bearing two chlorido ligands, and the derivative bearing one phosphane ligand presented the most promising toxicity profile in our in vitro screening, displaying a p53 dependent activity in colorectal cancer HCT116 cells. Finally, for the first time C^N cyclometallated gold(III) complexes were shown to be potent inhibitors of the zinc finger protein PARP-1, involved in the mechanisms of cisplatin resistance.
Introduction
Metallodrugs play an important role in the treatment of several diseases. Among them, cisplatin [cis-diamminedichlorido platinum(II)], discovered accidentally, 1 is widely used in every second chemotherapy due to its strong effects against ovarian, testicular and lung cancer. Unfortunately, anticancer therapy with cisplatin has a range of limitations, including resistance, limited spectrum of action and severe side effects, including nephrotoxicity. For this reason, since cisplatin's discovery, numerous Pt-based anticancer agents have been developed to minimize such harmful side effects. 2 However, to date, only two additional Pt(II)
compounds have achieved international marketing approval, carboplatin and oxaliplatin, although not being deprived of toxic effects. 3 In the effort to develop improved anticancer metallodrugs, several other metal complexes have been explored in vitro and in vivo, including compounds of Fe, Ru, Ti and Au. [4] [5] [6] On the basis of these chemical considerations, the peculiar properties of gold have been exploited for several applications. To date, many complexes containing Au in +1 and +3 oxidation states have shown therapeutic properties against cancer or inflammatory diseases. When exploiting the reactivity of gold derivatives against cells, one should bear in mind also the metal noble character. Thus, the stabilization of the oxidation states +1 and +3 is of paramount importance to observe any kind of biological activity. Otherwise, the metal center can ultimately undergo reduction process, thus leading to the formation of Au(0).
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In this context, the development of anticancer gold organometallics of various families has identified promising candidates with anticancer properties, including Au(I) alkynyl complexes, Au(I/III) N-heterocyclic carbene (NHC) complexes and Au(III) cyclometallated complexes. [8] [9] [10] [11] [12] The advantage of NHC and cyclometallated organometallic gold compounds is their relative stability with respect to other classical coordination complexes. There is evidence that Au compounds preferentially target proteins in biological environments, such as the Se-enzyme thioredoxin reductase (TrxR), [13] [14] [15] [16] Zn finger enzymes,17,18 as well as the membrane water and glycerol channels aquaglyceroporins. [19] [20] [21] Notably, increasing interest is given to the family of cyclometallated gold(III) complexes, in which the Au3+ ions are highly stabilized in physiological conditions. Recently, we reviewed the variety of cyclometallated gold(III) complexes of different scaffolds, namely (C^N)Au (C^N^N)Au, and (C^N^C)Au complexes. 8 For example, Fricker and coworkers reported the synthesis and biological activity of square-planar six-membered cycloaurated Au(III) compounds with a pyridinyl-phenyl linked backbone and two monodentate or one bidentate leaving group(s), which were able to inhibit the cysteine proteases cathepsins B and K in vitro. 22 Structure/activity relationships were investigated by modifications to the pyridinyl-phenyl backbone, and leaving groups, demonstrating optimal activity with substitution at the 6 position of the pyridine ring. In this study, the importance of the leaving groups was also highlighted. 22 Moreover, one of the derivatives containing thiosalicylate, as one of the ligands bound to the (C^N)Au scaffold, was tested in vivo against the HT29 human colon tumor xenograft model, where a modest decrease in tumor growth was observed compared to the untreated control tumor. 22 Taking into account these promising studies, we report here the synthesis and characterization of a new series of four gold(III) cyclometallated compounds of the general formula [Au(pyb-H)L1L2]n+ (pyb-H = C^N cyclometallated 2-benzylpyridine, L1 and L2 being 1,3,5-triazaphosphaadamantane (PTA), thio-ß-D-glucose tetraacetate (GluS-) or chlorido ligands; n = 0, 1). Notably, the PTA ligand was chosen for its good water solubility, while the GluS-ligand, was selected with the aim of facilitating uptake into cancer cells modulating the lipophilic/hydrophilic character, as well as via possible interaction with GLUT1 transporters. 23 containing 1,3,5-triazaphosphaadamantane (PTA), which is not toxic to cancer cells and is known in general to improve water solubility. Thus, by reacting 1 with one equivalent of PTA in presence of KPF 6 for 1.5 hours at room temperature, we obtained 2-PF 6 in very good yield (Scheme 1). Complexation of the phosphane ligand as well as the isomeric purity of 2-PF 6 were assessed by 31 P NMR showing the PF 6 -anion heptuplet signal centred at -144.4 ppm and a singlet of the coordinated phosphorous at -14.2 ppm, downfield shifted by 86 ppm with respect to the free phosphane ligand. Of the two possible geometrical isomers, trans-P-Au-N or trans-P-Au-C, the IR and 1 H NMR spectra, taken together, support a trans-P-Au-N arrangement.
Indeed, in the IR spectrum the Au-Cl stretching vibration is observed at values consistent with a chlorine trans to a carbon atom (see Experimental section) and in the 1 H NMR spectrum the H 6 proton (for numbering scheme, see Scheme 2) of the pyridine is strongly deshielded with respect to the free ligand (Dd = 0.44 ppm), as usually observed in related complexes and reflects the throughspace influence of the adjacent chloride ligand. X-ray-quality crystals of 2-PF 6 were obtained by slow diffusion of diethyl ether into an acetone solution and the structure in the solid state was solved by X-ray diffraction analysis. The solid state molecular structure of the cation is depicted in Fig. 1 S1 in the Supplementary material). The conformations of the two cations are similar and simply differ by a rotation of the PTA groups by about 19°, thus for simplicity reasons, the following description will only concern one of these cations (depicted in Fig. 1 ). The gold atom displays an almost regular square-planar coordination, with a slight distortion in the N-Au-C angle: 87.39(7)° (Fig. 1) . The bite of the six-membered cyclometallated ring, the bond lengths and angles involving the gold atom are comparable to those observed in 5-BF 4 by Fuchita ( In the absence of a crystal structure determination for complex 3, to discriminate between the two possible isomers, i.e. thioglucose in trans position to the carbon or to the nitrogen atom, (Figure S2 ), its far-IR (FIR) spectrum was compared to those of the other complexes, whose structures were known (2-PF 6 and 5-BF 4 ) or unambiguous (1 and 4). Indeed, in this range of energy we can observe the stretching bands of Au-Cl and Au-S bonds. The main FIR bands are shown in Table S2 in the Supplementary material.
The dichlorido complex 1 displays a medium band at 358 cm -1 and a strong one at 287 cm -1 , corresponding to the stretching of the Au-Cl bonds in trans position to the nitrogen and carbon atoms, respectively. In the case of 2-PF 6 , the FIR spectrum shows an intense band at 310 cm -1 close to the value (305 cm -1 ) observed for the analogous complex with PPh 3 , consistent with a chlorine trans to the carbon atom of the phenyl substituent. Compound 3 presents two bands: a broad one at 372 cm -1 corresponding to an Au-S bond trans to a nitrogen atom, and a strong one at 295 cm -1 corresponding to the Au-Cl bond in trans position to the carbon atom. As expected, the FIR spectra of 4 did not show any Au-Cl stretching band, but a broad double band with peaks at 375 and 369 cm -1 , consistent, respectively, with a sulfur trans to a nitrogen and to a carbon atom. 6 , 3 and 4 were screened for their antiproliferative properties in vitro in a panel of human cancer cell lines including ovarian adenocarcinoma (A2780), mammary carcinoma (MCF-7), lung carcinoma (A549) and colon carcinoma overexpressing p53 (HCT116 p53+/+) or p53 knock-out (HCT116 p53-/-), as well as on healthy human embryonic kidney cells (HEK-293T). The IC 50 was determined after 72 hours of incubation with different concentrations of compounds using the classical MTT test. The results are summarized in Table 2 .
Antiproliferative activity Compounds 1, 2-PF
In general, the new cyclometallated complexes 2-PF 6 , 3 and 4 were more toxic than their precursor 1, containing two chlorido ligands, in all cell lines with the exception of the A549 cell line in which most of the gold complexes appeared to be poorly toxic. The phosphane-containing complex 2-PF 6 presents the most interesting toxicity profile, comparable to that of cisplatin in A2780 cells (IC 50 = 2.7 ± 0.2 and 1.9 ± 0.6 µM, respectively). Furthermore, complex 2-PF 6 is twice as toxic as cisplatin against HCT116+/+ cells (IC 50 = 2.1 ± 0.7 and 5.3 ± 0.2 µM) and poorly effective on the HCT116 p53-/-(IC 50 = 14.0 ± 1.1 µM). The latter result suggests similar dependence on p53 pathways for compound 2-PF 6 as for cisplatin. In terms of selectivity, 2-PF 6 is also ca. 3-fold less toxic on the HEK-293T cells compared to the HCT116 p53+/+. Compounds 3 and 4 showed overall moderate antiproliferative properties, and their inactivity rules out the idea that the tetra-acetylated β-D-glucose-1-thiolato ligand may enhance the uptake of the compounds, for example through GLUT-1 transporters. Indeed, our previously reported studies on Au(I) NHC complexes with similar thio-sugar ligands also showed scarce cytotoxic effects most likely due to poor gold uptake. 
PARP-1 inhibition
In order to further investigate the mechanisms of action of our organometallic compounds, and inspired by our recent results that indicate that some cytotoxic gold(III) compounds are efficient inhibitors of the zinc-finger protein PARP-1, 17 we tested complexes 1 and 2-PF 6 on the purified human enzyme as described in the experimental section. Remarkably, potent PARP-1 inhibition was indeed observed with both compounds: 1 with IC 50 = 1.30 ± 0.40 nM, and 2-PF 6 with IC 50 = 1.87 ± 0.20 nM, respectively. Notably, these values are in the same range of those previously observed for Au(III) complexes with N-donor ligands. 
Conclusions
The potential of organometallic compounds for biological applications, including as anticancer agents, have been demonstrated by numerous studies. 30 Here, we report the synthesis and characterization of a new series of (C^N) cyclometallated gold(III) complexes bearing different ancillary ligands selected to confer different reactivity and biological properties to the resulting compounds, such as PTA for increased water-solubility, and thio-sugar moieties to influence uptake and reduce exchange with biological nucleophiles. The X-ray structure of compound 2-PF 6 was solved and revealed the typical square-planar geometry of the gold(III) cation, as well as the coordination of the phosphane ligand trans to the nitrogen. Compound 1, which is the precursor of the series, was poorly cytotoxic on all cell lines, while the phosphane-containing compound 2-PF 6 shows the most promising results against the HCT116 cancer cell line overexpressing p53. Interestingly, compounds 1 and 2-PF 6 inhibited the zinc-finger enzyme PARP-1 in nM concentrations, suggesting the possible design of selective inhibitors and the use of organometallic gold compounds in combination therapies with other anticancer drugs. PARP inhibitors are currently highly investigated for their selective cytotoxic properties and can be considered as DDR inhibitors, 31 which can be used in combination with classical DNA damaging agents for optimizing the therapeutic outcome. Overall, our study shows the potential for improvement of the biological properties of organometallic gold-based compounds by tuning their coordination environment. Further studies are ongoing to evaluate the mechanisms of transport and possible targets for this new series of gold compounds, including interactions with nucleic acids.
Experimental section

General Remarks
All reactions were carried out under purified argon using Schlenk techniques. Solvents were dried and distilled under argon before use. A round-bottom flask was charged with 1 (1 eq, 50 mg, 0.115 mmol) and KPF 6 (5 eq, 106 mg, 0.573 mmol) in suspension in acetone (5 mL). PTA (1 eq, 18 mg, 0.115 mmol) was added to the mixture at room temperature leading to the solubilisation of the starting Au complex. The reaction mixture was maintained at room temperature for 1.5 h. 
[(Au(py b -H)(GluS)Cl] (3)
A round-bottom flask was charged with 1 (1 eq., 50 mg, 0.115 mmol), thio-β-D-glucose tetraacetate (GluSH) (1 eq., 42 mg., 0.115 mmol) and Na 2 CO 3 (2 eq., 24 mg, 0.230 mmol) in suspension in dichloromethane (5 mL). The reaction was maintained at room temperature for around 1.5 h (until the solution turned yellow). The solution was filtered through Celite® and concentrated under reduced pressure. Upon addition of pentane a yellow precipitate was formed that was filtered off and dried under vacuum to give compound 3 as a 1:1 mixture of diastereomers (83.9 mg, 96 % yield 
